Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

VolitionRx Limited’s triage test results validated in prospective trial

Wednesday, March 1, 2017 8:15
% of readers think this story is Fact. Add your two cents.

VolitionRx Limited (NYSEMKT:VNRX) has presented data at the World Congress of GI Endoscopy 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.QTM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.

“This is a key clinical milestone in the launch of our Nu.QTM Triage product. This validation study, in a second population of 1,961 subjects, greatly assists us with sales and marketing efforts in the EU and Asia,” said Louise Day, Chief Marketing and Communications Officer at VolitionRx.

The lead author of the study, Dr. Marielle Herzog, commented, “This data confirms the role that the Nu.QTM Triage test can play in accelerating the diagnosis of colorectal cancer.”

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.